Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-08-13 Interim / Quarterly Rep…
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2024
2024-08-13 English
DEFA14A
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed by Seres Therapeutics, Inc. dated August 13, 2024. It announces the company's second quarter 2024 financial results and provides business updates, including details about a clinical trial and a significant asset sale transaction. The document includes a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2). The presence of detailed quarterly financial results and operational updates indicates this is an Earnings Release. The document is not a full quarterly report (10-Q) but an initial announcement of quarterly financial results and highlights, consistent with the definition of an Earnings Release (ER).
2024-08-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Seres Therapeutics, Inc. It reports the announcement of financial results for the quarter ended June 30, 2024, and provides operational updates. It also includes a corporate presentation posted on the company's website. The document explicitly states that the press release and presentation are furnished as exhibits and are not filed, indicating this is a current report announcing events rather than a full financial report. The document is not a full quarterly or annual report but a current report disclosing recent material events, including earnings release and presentation. Therefore, the document is best classified as an Earnings Release (ER) because it announces quarterly financial results and operational updates, accompanied by a press release and presentation. The length (over 10,000 characters) and content confirm it is more than a brief announcement but not a full interim report with detailed financial statements, so ER is appropriate.
2024-08-13 English
DEFA14A
Call Transcript Classification · 100% confidence The document is a transcript of an investor conference call held by Seres Therapeutics on August 6, 2024. It includes detailed discussion of a significant transaction involving the sale of VOWST assets to Nestle, financial terms of the deal, strategic outlook, and Q&A with analysts. The content is a verbatim transcript of the call, including prepared remarks and Q&A, which is typical of earnings or investor conference call transcripts. There is no indication that this is a proxy statement or solicitation material despite the initial SEC form header, as the main body is a call transcript. The presence of multiple speakers, detailed financial and strategic discussion, and Q&A confirms this is a Call Transcript (CT).
2024-08-07 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filing related to a proposed transaction (an Asset Purchase Agreement) between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. It discusses solicitation of proxies for a stockholder meeting to approve the transaction and references the definitive proxy statement that will be sent to stockholders. The document includes forward-looking statements and instructions on where to find the definitive proxy statement and other SEC filings. It is clearly a solicitation material related to a proxy statement and not the proxy statement itself or the transaction agreement. The document is not a full annual report, earnings release, or merger filing but is related to proxy solicitation for a transaction. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2024-08-06 English
DEFA 14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or soliciting material related to a shareholder vote. It includes detailed information about a proposed transaction (asset purchase agreement with Nestle), forward-looking statements, and instructions for stockholders to read the definitive proxy statement when available. It explicitly states it is soliciting material under SEC rules and references the upcoming definitive proxy statement for stockholder approval. This type of document is classified as Proxy Solicitation & Information Statement (PSI). The document length (10,757 characters) and content confirm it is not merely an announcement but a full solicitation document. Therefore, the correct classification is PSI with high confidence.
2024-08-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.